Cognition Therapeutics, Inc. - Common Stock (CGTX)
1.5400
-0.1200 (-7.23%)
NASDAQ · Last Trade: Aug 17th, 11:46 PM EDT
Detailed Quote
Previous Close | 1.660 |
---|---|
Open | 1.670 |
Bid | 1.570 |
Ask | 1.590 |
Day's Range | 1.520 - 1.970 |
52 Week Range | 0.2223 - 1.970 |
Volume | 13,522,626 |
Market Cap | 100.04M |
PE Ratio (TTM) | -2.299 |
EPS (TTM) | -0.7 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 8,207,888 |
Chart
About Cognition Therapeutics, Inc. - Common Stock (CGTX)
Cognition Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer’s disease and other forms of dementia. The company leverages its proprietary drug discovery platform to identify and advance small molecule therapeutics that target the underlying mechanisms of these conditions, aiming to improve cognitive function and enhance the quality of life for patients. By utilizing a unique approach that involves modulating cellular pathways associated with neurodegeneration, Cognition Therapeutics is dedicated to addressing significant unmet medical needs in the field of neurology. Read More
News & Press Releases
Via Benzinga · August 14, 2025
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · August 14, 2025
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · August 13, 2025
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via Chartmill · August 13, 2025
Via Benzinga · August 13, 2025
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday that it will be acquired by global private equity firm Advent in an all-cash transaction
Via Benzinga · August 13, 2025
Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine.
Via Benzinga · August 13, 2025
Via Benzinga · August 12, 2025
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · August 12, 2025
- Cognition and FDA align on enriched population, study design, and endpoints -
By Cognition Therapeutics, Inc. · Via GlobeNewswire · August 12, 2025
- Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting -
By Cognition Therapeutics, Inc. · Via GlobeNewswire · August 7, 2025
- Zervimesine’s impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer’s patients most likely to benefit from zervimesine treatment -- Plasma and CSF biomarkers support zervimesine’s impact on Alzheimer’s disease biology -
By Cognition Therapeutics, Inc. · Via GlobeNewswire · July 29, 2025
Power Metallic Mines Inc. (TSXV: PNPN | OTCQB: PNPNF) has launched a major Q2–Q3 2025 exploration push across its key Quebec polymetallic zones—Lion, Tiger, and Nisk. With three drill rigs currently operating and a fourth en route, the company is targeting over 20,000 meters of drilling this summer. The expanded program is backed by upgraded core logging facilities and an expanded field operations team.
Via AB Newswire · July 10, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · July 10, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the most active stocks in today's session.
Via Chartmill · July 10, 2025
Via Benzinga · July 10, 2025
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · July 10, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · July 10, 2025
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · July 10, 2025
Via Benzinga · July 10, 2025
Via Benzinga · July 7, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · July 7, 2025
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · July 7, 2025